Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Spondyloarthritis
•
Psoriatic arthritis
•
General Rheumatology
•
Cardiology
•
Cardio-Rheumatology
•
Pericarditis
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
Related Questions
How do you approach managing nausea and GI side effects when initiating methotrexate?
In a patient with isolated HLA B27+ anterior uveitis, how long would you continue immunosuppressive therapy?
Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?
Would you recommend avoiding use of bimekizumab in patients at higher risk of fungal infections such as patients with diabetes who are on SGLT-2 inhibitors which also increase the risk of fungal infections?
What is your approach to differentiating tender spots (as in fibromyalgia) and enthesitis (as in axSpA)?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
Would you switch to bimekizumab if a patient with psoriatic arthritis who is already on an IL-17 inhibitor has breakthrough skin or joint disease?
How do you approach cardiovascular risk management in patients with rheumatic disease?
Do you generally attempt to taper and discontinue biologics in a patient with psoriatic arthritis who is in clinical remisson?
Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?
